By Will Feuer

 

MeiraGTx Holdings said it has received a $30 million investment from French pharmaceutical company Sanofi, and said the company has been approached by multiple parties about certain assets.

MeiraGTx, a clinical-stage gene-therapy company, said Sanofi bought 4 million shares at a price of $7.50 a share. Sanofi will receive a right of first negotiation for the use of MeiraGTx's Riboswitch gene-regulation technology for various uses, including in GLP-1 drugs.

The company said it is also actively pursuing options after multiple parties approached MeiraGTx with interest in some of the company's assets. MeiraGTx has hired Evercore as a financial advisor and Wachtell, Lipton, Rosen & Katz as legal advisor.

 

Write to Will Feuer at Will.Feuer@wsj.com

 

(END) Dow Jones Newswires

October 30, 2023 07:59 ET (11:59 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024 Haga Click aquí para más Gráficas Sanofi.
Sanofi (EU:SAN)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024 Haga Click aquí para más Gráficas Sanofi.